About Inozyme Pharma
Inozyme Pharma is a Healthcare company based in Cambridge (United States) founded in 2016 by Axel Bolte, and was acquired by BioMarin Pharmaceutical in May 2025. Inozyme Pharma has raised $116.4 million across 2 funding rounds from investors including BioMarin Pharmaceutical, TD Securities and RA Capital. The company has 59 employees. Its chief executive, as recorded, is Axel Bolte. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Diversified. Its competitors include Alnylam, Ultragenyx and BioMarin Pharmaceutical; 3 of its 3 listed competitors have raised funding.
Company details
Developer of treatments for rare and debilitating metabolic diseases. The companys product line include INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in metabolites.
- Headquarters Cambridge, United States
- Employees 59
- Founders Axel Bolte
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website inozyme.com
- Social LinkedIn X Facebook
- Acquired by BioMarin Pharmaceutical (May 2025)
- Net Profit$102.02 M (USD)43as on Dec 31, 2024
- EBITDA-$104.03 M (USD)-38as on Dec 31, 2024
- Total Equity Funding$116.4M (USD)
in 2 rounds
- Latest Funding Round$67.4M (USD), Series A
Apr 2019
- InvestorsBioMarin Pharmaceutical
& 9 more
- Employee Count59
- Acquired byBioMarin Pharmaceutical
(May 2025)
Funding Insights of Inozyme Pharma
Inozyme Pharma has successfully raised a total of $116.4M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $67.4 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $116.4M
- Total Rounds 2
- Last Round Series A — $67.4M
- First Round $49M
(Nov 2017)
- Investors Count 9
All 2 funding rounds of Inozyme Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $67.4M | Series A | – | Sofinnova Investments, Pivotal bioVenture Partners | |
| Nov 2017 | $49M | Series A | – | Longitude Capital |
10 investors in total: 10 institutional.
Investors in Inozyme Pharma
Inozyme Pharma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include BioMarin Pharmaceutical, TD Securities and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Life-Sciences focused Early stage Corporate VC Firm investing in the US | sanofiventures.com | Paris, France | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States | |
A global healthcare investment firm supporting therapeutic-focused companies. | 2017 | pivotalbiovp.com | San Francisco, United States | |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. | 1997 | biomarin.com | San Rafael, United States |
Investor details for Inozyme Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Inozyme Pharma
32 people are tracked at Inozyme Pharma (10 in leadership, 15 in board & advisors, 7 in team); the tracked headcount is 59.
| Name | Role | Group |
|---|---|---|
Axel Bolte | Co-Founder & CEO | Leadership |
Yves Sabbagh | SVP & Chief Scientific Officer | Leadership |
Brian W. Pusch | Co-Founder | Leadership |
Diane Piper | Head Of Biometrics - Executive Director Of Biometrics | Leadership |
Denis Schrier, PhD | Vice President, Toxicology | Leadership |
Jinyong Huang | Sr. Director, Statistical Programming | Leadership |
Elizabeth Alessi | Vice President, Regulatory Affairs, Medical Writing, And Pharmacovigilance | Leadership |
Daniel Ortiz | Senior Director of Research | Leadership |
David Thompson | Chief Development Officer | Leadership |
Katie Wray, PharmD | Director, Medical Affairs | Leadership |
Robert Terkeltaub | Member of Scientific Advisory Board | Board & advisors |
Jouni Uitto | Member of Scientific Advisory Board | Board & advisors |
Ed Mathers | Director | Board & advisors |
Reinaldo M. Diaz | Director | Board & advisors |
Sarah Bhagat | Director | Board & advisors |
Charles O’Neill | Member of Scientific Advisory Board | Board & advisors |
Martin Edwards | Director | Board & advisors |
Michael A. Levine | Chairperson, Clinical Advisory Board | Board & advisors |
Rob Hopfner | Director | Board & advisors |
Joseph Schlessinger | Member of Scientific Advisory Board | Board & advisors |
12 more people are available in the full profile.
Complete people profiles for Inozyme Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Inozyme Pharma
5 dated milestones of Inozyme Pharma across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Inozyme Pharma is founded.
- Funding First funding round of $49.0M.
- Funding Latest funding round, Series A, of $67.4M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by BioMarin Pharmaceutical.
Competitors of Inozyme Pharma
Inozyme Pharma has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and BioMarin Pharmaceutical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| biomarin.com | 1997 | San Rafael, United States | $37.5M | 2,124 | Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. |
Detailed competitors of Inozyme Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Inozyme Pharma
The website of Inozyme Pharma (inozyme.com) receives about 6.1K visits a month.
- Monthly visits6.1K
▲ 6.9% vs previous month
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Inozyme Pharma (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inozyme Pharma
Complete news archive for Inozyme Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inozyme Pharma
Inozyme Pharma was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Inozyme Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Axel Bolte is the CEO of Inozyme Pharma, as recorded in our data. They have also founded this company.
Inozyme Pharma is a funded company, having raised a total of $116.4M across 2 funding rounds to date. The company's 1st funding round was a Series A of $49M, raised on Nov 2017.
Inozyme Pharma has 59 employees.
Developer of treatments for rare and debilitating metabolic diseases. The companys product line include INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in metabolites.
Inozyme Pharma's top competitors include Alnylam, BioMarin Pharmaceutical and Ultragenyx.
Inozyme Pharma has 10 investors. Key investors include BioMarin Pharmaceutical, TD Securities, RA Capital, Sofinnova, and Rock Springs Capital.
Yes. Inozyme Pharma was acquired by BioMarin Pharmaceutical in May 2025.